Astrazeneca PLC revenue

Astrazeneca PLC's revenue was $58.74bn in fiscal 2025, up 8.6% on the year before. Since fiscal 2015 ($24.71bn) it has grown at a compound 9.0% a year.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Astrazeneca PLC: revenue history, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	24.7	23.0	22.5	22.1	24.4	26.6	37.4	44.4	45.8	54.1	58.7
Growth on the year before	—	−6.9%	−2.3%	−1.7%	+10.4%	+9.2%	+40.6%	+18.5%	+3.3%	+18.0%	+8.6%
Gross profit	20.1	18.9	18.1	17.2	19.5	21.3	25.0	32.0	37.5	43.9	48.1
Gross margin	81.2%	82.1%	80.8%	77.7%	79.8%	80.1%	66.8%	72.1%	82.0%	81.1%	81.9%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Astrazeneca PLC	$58.74bn	8.6%	—
Pfizer	$63.70bn	-0.2%	-7.0%
Merck & Co.	$66.57bn	4.6%	4.5%
Bristol Myers Squibb	$50.03bn	4.2%	3.6%
Novo Nordisk A S	$46.82bn	11.1%	—
GSK plc	$43.09bn	7.5%	—

Compare with peers

Head to head: AZN vs PFE AZN vs MRK AZN vs BMY AZN vs NVO

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Astrazeneca PLC's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Astrazeneca PLC.